Moreover, our findings indicate that PTPN3 was upregulated in later clinical stages in ACC and COAD, while it was significantly downregulated in later stages in KIRC and TGCT, suggesting that monitoring PTPN3 expression may predict cancer progression in clinical settings. This evidence concerns the gene PTPN3 and cancer.